2, 5, and 10 years
1, 3, and 5 years
2, 4, and 8 years
None of theabove
Development of individualized disease management plan with risk level in mind
Reduce the risk of disease occurence and recurrence in families at risk
Reduce the risk of glaucoma
Increased surveillance to identify first sign of AMD
Age, Family History , Phenotype
Age, Average Life expectancy and Genotype
Genotype, Phenotype, Age and Environment
Current stage of AMD, Smoking Status and Genotype
Anyone with a family history of AMD
55 years or older, Caucasian, with preexisting early or intermediate AMD
Smokers with advanced AMD
55 years of older with a family history of AMD
Monitoring patients using a fixed surveillance schedule based on their stage of disease
Determining a patients genotype result for each SNP tested
Utilizing SNPs, alone and in combination with other patient information
Comparing patient's risk profile with the risk profiles of all AREDS patients of the same grade
RetnaGene LR genotyping includes 12 SNPs associated with AMD
RetnaGene AMD genotyping includes 12 SNPs associated with AMD
RetnaGene LR genotyping includes 8 SNPs associated with AMD
RetnaGene AMD genotyping includes 8 SNPs associated with AMD
Show the prevalence of advanced AMD in the United States
Give the patient's absolute and relative risk of developing advanced AMD in an individuals lifetime
Identify at-risk Caucasians, 55 years or older with early onset of AMD
Manage patient's risk of progression so that vision may be preserved in both eyes
Age, Genotype, Phenotype, and Environment
Genotype, Age, Phenotype, and Average Life Expectancy
Age, Genotype, Phenotype, and Family History
Age, Average Life Expectancy, and Genotype
Average Life Expectancy
All of the above
RetnaGene AMD tests risk of progressing to CNV.
RetnaGene AMD tests risk of progressing to GA.
RetnaGene LR tests risk of developing CNV.
RetnaGene LR tests risk of developing GA.
Fixed surveillance is the best method of detecting early conversion to CNV.
RetnaGene AMD research has shown that all AMD patients of the same AREDS Simplified Severity Scale grade should be followed on the same schedule in order to have the least missed conversions to CNV.
RetnaGene AMD increases the visit burden for retina specialists in exchange for increased detection of early CNV.
Risk-based surveillance may reduce the number of missed conversions to CNV by about 8%.
Advanced AMD patients
Family members of advanced AMD patients
Advanced Dry AMD patients
Their staff members
Optimize the monitoring schedule for an individual patient
Assist the ECP in determining need for additional home monitoring devices
Increased anti-VEGF treatments
Improve patient compliance with vitamin therapies and lifestyle change recommendations